Difluoromethylornithine
Disease Related To Solid Organ Transplantation
Explore 18 assets in Disease Related To Solid Organ Transplantation →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Wisconsin, Madison
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00204789CT.gov Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Solid Organ Transplantation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Difluoromethylornithine (this asset) | University of Wisconsin, Madison | P2 | B · 57 |
| Tacrolimus | The Second Hospital of Tangshan | P4 | BBB |
| Angiotensin Ii | University of California, San Francisco | P4 | BBB |
| Equine Atg | University Hospital, Toulouse | P4 | BB |
| Everolimus | Novartis Pharmaceuticals | P3 | BB |
| Semaglutide | University Health Network, Toronto | P4 | BB |
| Sitagliptin | University Health Network, Toronto | P4 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Noradrenaline | University of California, Los Angeles | P4 | BB |
+26 more in the Disease Related To Solid Organ Transplantation cohort
Other indications for Difluoromethylornithine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Neoplasm | — | P2 | B · 57 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 41 |
| Lung Cancer | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Difluoromethylornithine in Disease Related To Solid Organ Transplantation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/difluoromethylornithine-disease-related-to-solid-organ-transplantation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →